Preclinical science regarding cannabinoids as analgesics: an overview.
Modern pharmacology of cannabinoids began in 1964 with the isolation and partial synthesis of delta-9-tetrahydrocannabinol, the main psycho-active agent in herbal cannabis. Since then, potent antinociceptive and antihyperalgesic effects of cannabinoid agonists in animal models of acute and chronic pain; the presence of cannabinoid receptors in pain-processing areas of the brain, spinal cord and periphery; and evidence supporting endogenous modulation of pain systems by cannabinoids has provided support that cannabinoids exhibit significant potential as analgesics. The present article presents an overview of the preclinical science.
Lynch
M E
ME
Pain Management Unit, Queen Elizabeth II Health Sciences Centre, Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia. mary.lynch@dal.ca
D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002186:Cannabinoids / Q000494:pharmacology / Q000627:therapeutic use*; D063388:Endocannabinoids / Q000378:metabolism; D010146:Pain / Q000188:drug therapy*; D043882:Receptors, Cannabinoid / Q000378:metabolism
D000700:Analgesics; D002186:Cannabinoids; D063388:Endocannabinoids; D043882:Receptors, Cannabinoid